Checkpoint Therapeutics, Inc. is a commercial-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Its product candidates include UNLOXCYTTM (cosibelimab-ipdl) for the treatment of adults with metastatic cSCC or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Additionally, the Company is engaged in evaluating its lead investigational small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	371M 324M 299M 277M 525M 35.38B 534M 3.58B 1.4B 17.38B 1.39B 1.36B 60.19B	P/E 2023	-1.23x	P/E 2024	-2.26x
Enterprise Value	364M 319M 294M 272M 516M 34.75B 524M 3.52B 1.38B 17.07B 1.37B 1.34B 59.12B	EV / Sales 2023	475x	EV / Sales 2024	3,650x
Free-Float	47.41%	Yield 2023 *	-	Yield 2024	-

02/06/25	Checkpoint Therapeutics, Inc.(NasdaqCM:CKPT) dropped from S&P TMI Index	CI
31/05/25	Sun Pharmaceutical Industries Limited completed the acquisition of Checkpoint Therapeutics, Inc. from Fortress Biotech, Inc., Armistice Capital Master Fund Ltd., managed by Armistice Capital LLC and others.	CI
31/05/25	Sun Pharmaceutical Industries Completes Acquisition Of Checkpoint Therapeutics	RE
31/05/25	Fortress Biotech Closes Sale of Checkpoint Therapeutics Unit	MT
31/05/25	Checkpoint Therapeutics, Inc. Appoints Zvi Albert as Chief Financial Officer	CI
31/05/25	Checkpoint Therapeutics, Inc. Announces Board and Executive Changes	CI
30/05/25	Checkpoint Therapeutics, Inc.(NasdaqGM:CKPT) dropped from NASDAQ Composite Index	CI
14/05/25	Checkpoint Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
28/03/25	Checkpoint Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
28/03/25	Checkpoint Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
11/03/25	HC Wainwright Downgrades Checkpoint Therapeutics to Neutral From Buy, $20 Price Target	MT
11/03/25	Lake Street Downgrades Checkpoint Therapeutics to Hold From Buy, $4.10 Price Target	MT
11/03/25	Checkpoint Therapeutics to Be Acquired by India's Sun Pharmaceutical -- Checkpoint Shares Jump Monday	MT

11/03/25	HC Wainwright Downgrades Checkpoint Therapeutics to Neutral From Buy, $20 Price Target	MT
11/03/25	Lake Street Downgrades Checkpoint Therapeutics to Hold From Buy, $4.10 Price Target	MT
20/12/23	B. Riley Lowers Checkpoint Therapeutics' Price Target to $4 From $8, Keeps Buy Rating	MT
22/08/23	B. Riley Lowers Checkpoint Therapeutics' Price Target to $8 From $15, Keeps Buy Rating	MT
16/08/23	Lake Street Adjusts Checkpoint Therapeutics Price Target to $14 From $16, Maintains Buy Rating	MT

31/05/25	Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics	AQ
14/05/25	Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates	AQ
30/04/25	CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT	BU
28/03/25	Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates	AQ
15/03/25	CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT	BU

23/08/24	Avery Dennison Corporation : Todo lo que busca
19/07/24	Zscaler, Inc.: de kunst van de Zero Trust-aanpak
18/07/24	Zscaler: l'arte dell'approccio zero trust
16/07/24	Zscaler, Inc.: El arte del enfoque de confianza cero
16/07/24	Zscaler : l'art de l'approche zero trust

Checkpoint Therapeutics Inc Stock Other OTC

Stocks

US1628281073

Biotechnology & Medical Research

Valuation: Checkpoint Therapeutics Inc

Latest news : Checkpoint Therapeutics Inc

Analysts' recommendations: Checkpoint Therapeutics Inc

Press Releases: Checkpoint Therapeutics Inc

News in other languages: Checkpoint Therapeutics Inc

Quotes and Performance

Managers and Directors: Checkpoint Therapeutics Inc

Bio Therapeutic Drugs

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CHECKPOINT THERAPEUTICS INC	-0.50%	+2.05%	-	-	357M
ARGENX SE	-0.23%	-4.31%	+63.78%	+126.11%	56.98B
WUXI APPTEC CO., LTD.	+4.91%	-0.19%	+73.70%	+92.14%	53.58B
INSMED INCORPORATED	+1.48%	+5.97%	+22.59%	+495.47%	25.63B
BIONTECH SE	-0.59%	-4.68%	-16.82%	-12.99%	23.51B
WUXI BIOLOGICS (CAYMAN) INC.	+2.43%	+1.06%	+47.70%	-0.11%	19.43B
GENMAB A/S	-1.01%	+2.54%	+37.40%	-25.01%	18.12B
PHARMAESSENTIA CORPORATION	-6.84%	+2.18%	+203.03%	+348.11%	16.46B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+8.74%	+3.51%	+53.81%	-	14.13B
EXELIXIS, INC.	+1.76%	+2.24%	+29.57%	+195.70%	14.35B
Average	+1.01%	+0.86%	+57.20%	+152.43%	26.91B
Weighted average by Cap.	+1.40%	-0.31%	+57.38%	+142.94%

	2023	2024
Net sales	103K 90.1K 83.09K 76.88K 146K 9.83M 148K 995K 390K 4.83M 387K 378K 16.72M	41K 35.87K 33.08K 30.6K 58.09K 3.91M 59.06K 396K 155K 1.92M 154K 151K 6.66M
Net income	-51.85M -45.36M -41.83M -38.7M -73.45M -4.95B -74.68M -501M -196M -2.43B -195M -190M -8.42B	-56.24M -49.2M -45.37M -41.98M -79.68M -5.37B -81.01M -543M -213M -2.64B -211M -207M -9.13B
Net Debt	-4.93M -4.31M -3.98M -3.68M -6.98M -470M -7.1M -47.61M -18.66M -231M -18.5M -18.1M -800M	-6.6M -5.78M -5.33M -4.93M -9.36M -630M -9.51M -63.8M -25.01M -310M -24.79M -24.26M -1.07B